Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
about
Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.Primary adrenal nodular lymphocyte-predominant Hodgkin lymphoma: A case report and review of the literatureRole of Radiotherapy in Modern Treatment of Hodgkin's LymphomaHodgkin lymphoma.Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphomaLymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.Hodgkin's lymphoma: current treatment strategies and novel approaches.The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.State of the art in the treatment of Hodgkin lymphoma.Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.Advances in the treatment of Hodgkin lymphoma.Modern management of lymphocyte-predominant Hodgkin lymphoma.VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma.ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma.Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.The GHSG Approach to Treating Hodgkin's Lymphoma.Open questions in the management of nodular lymphocyte predominant hodgkin lymphoma.Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group.[IF-RT alone remains gold standard for stage IA nodular lymphocyte-predominant Hodgkin lymphoma].High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival.Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease: a multi-institutional experience.The German evidence-based guidelines for Hodgkin's lymphoma. Aspects for radiation oncologists.A Case of Chemotherapy-Refractory "THRLBCL like Transformation of NLPHL" Successfully Treated with Lenalidomide.Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)
P2860
Q30978936-BB548007-FC5E-4A55-9B20-5FA9C5370364Q33406827-9EB59EEA-AD14-4F7C-BBF1-5E2D7D07B519Q33968094-8C737EE3-22B6-4858-A825-55B4181FD4F0Q34235785-F6CBB604-AD9B-4FD5-865C-137DD86B5A84Q34643277-73C51254-4B7A-43B4-B7A1-21AD1EF71EB9Q34664223-6FD0B060-FBB2-4767-B084-DCE9EF09F275Q36337603-0DF1E200-FEF3-47FD-807D-8CE97DDE9572Q36440046-2CE666B8-05B9-467B-A21D-CD5A07E3BE70Q36479283-4BFE265E-B96F-4384-ACE4-47CE8D159162Q37717839-F55694AD-8F05-47C1-9F95-A9CA57CE7F38Q37810114-E18E7319-E06E-4D5F-9CF8-6F771C9E9A56Q37910912-A5E0DE7A-385E-4CFD-8E03-A504F5A7D4B8Q38017914-5B6FA302-C8D5-40D7-A82F-52A23247453BQ38044928-6825CB32-2D58-4D45-A709-E39D96DC2B87Q38051197-BFEA9D6C-E60D-4592-8807-7BA8F7A434EEQ38080591-B9AC26FB-59B3-49FB-8C24-B51CF4122302Q38115227-F6FD6EA5-6C6B-4078-BF56-AF8A16999CE5Q38195016-7AED183F-9ED9-4351-9223-D615AF10D0DDQ38205880-D448D3EE-61E1-4F43-932A-2E69EC2AAD19Q38205923-D6C97215-066D-4C5D-9E4F-C47334F396DDQ38506223-020B77A9-A4E4-4C21-96A2-8BD071A4C887Q38632629-C9E1823F-B1F0-482C-86F7-34C94380F662Q39904031-181AC20E-6EB6-4562-B2E8-AAFFD1BD718AQ40747471-3585C4A4-C2EC-42B8-8105-67E30D839975Q41220681-7B29BB1B-562A-4B27-A7A9-EA517971F592Q47877461-B426EEE3-25ED-4423-8A79-E1CC95663485Q53081684-20F521C0-1598-4EE7-B513-F87AE87D6CF3Q53084551-40C1A820-353C-40D8-A639-6E2BB44F3552Q53112256-1167F438-4238-40FA-85BB-7ED360DE074EQ53431646-DF3BCA8E-B67B-4CF0-A498-FE4FA232475EQ57225717-1F288348-9DD3-4CC1-8441-2E0A9061083C
P2860
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@ast
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@en
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@nl
type
label
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@ast
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@en
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@nl
prefLabel
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@ast
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@en
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@nl
P2093
P2860
P356
P1433
P1476
Extended field radiotherapy, c ...... an Hodgkin Study Group (GHSG).
@en
P2093
A Gossmann
C Brillant
H K Müller-Hermelink
K Wingbermühle
M V Bollen
P2860
P304
P356
10.1093/ANNONC/MDI323
P577
2005-08-10T00:00:00Z